IL257470B2 - תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך - Google Patents

תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך

Info

Publication number: IL257470B2
Authority: IL; Israel
Prior art keywords: compound; represented; formula; subject; alkoxy
Prior art date: 2018-02-11

Application number

IL257470A

Other languages

English (en)

Other versions

IL257470A (he

IL257470B1 (he

Original Assignee

Ben Gurion Univ Of The Negev Research And Development Authority

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-02-11

Filing date

2018-02-11

Publication date

2023-12-01

2018-02-11 Application filed by Ben Gurion Univ Of The Negev Research And Development Authority filed Critical Ben Gurion Univ Of The Negev Research And Development Authority

2018-02-11 Priority to IL257470A priority Critical patent/IL257470B2/he

2018-02-12 Priority to CA3053309A priority patent/CA3053309C/en

2018-02-12 Priority to AU2018218003A priority patent/AU2018218003B2/en

2018-02-12 Priority to EP18709084.0A priority patent/EP3579824A1/en

2018-02-12 Priority to CN201880024446.4A priority patent/CN110505872A/zh

2018-02-12 Priority to PCT/IL2018/050161 priority patent/WO2018146689A1/en

2018-02-12 Priority to US16/485,416 priority patent/US11857516B2/en

2018-03-29 Publication of IL257470A publication Critical patent/IL257470A/he

2023-08-01 Publication of IL257470B1 publication Critical patent/IL257470B1/he

2023-08-25 Priority to US18/456,178 priority patent/US12576047B2/en

2023-12-01 Publication of IL257470B2 publication Critical patent/IL257470B2/he

Links

150000001875 compounds Chemical class 0.000 title claims description 32
230000035558 fertility Effects 0.000 title claims description 11
108010017842 Telomerase Proteins 0.000 title description 15
230000003213 activating effect Effects 0.000 title description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 10
229910052736 halogen Inorganic materials 0.000 claims description 10
150000002367 halogens Chemical class 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 9
125000001188 haloalkyl group Chemical group 0.000 claims description 9
230000001737 promoting effect Effects 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
125000005055 alkyl alkoxy group Chemical group 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
230000002710 gonadal effect Effects 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
230000036512 infertility Effects 0.000 claims 2
208000000509 infertility Diseases 0.000 claims 2
231100000535 infertility Toxicity 0.000 claims 2
208000017701 Endocrine disease Diseases 0.000 claims 1
208000026350 Inborn Genetic disease Diseases 0.000 claims 1
244000089486 Phragmites australis subsp australis Species 0.000 claims 1
208000006994 Precancerous Conditions Diseases 0.000 claims 1
208000030172 endocrine system disease Diseases 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
230000004720 fertilization Effects 0.000 claims 1
208000016361 genetic disease Diseases 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000002028 premature Effects 0.000 claims 1
230000010009 steroidogenesis Effects 0.000 claims 1
-1 arylalkylenesulfonyl Chemical group 0.000 description 33
125000003118 aryl group Chemical group 0.000 description 12
125000001072 heteroaryl group Chemical group 0.000 description 9
125000000592 heterocycloalkyl group Chemical group 0.000 description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
150000001299 aldehydes Chemical class 0.000 description 6
125000003342 alkenyl group Chemical group 0.000 description 6
125000002877 alkyl aryl group Chemical group 0.000 description 6
125000005213 alkyl heteroaryl group Chemical group 0.000 description 6
125000004414 alkyl thio group Chemical group 0.000 description 6
125000000304 alkynyl group Chemical group 0.000 description 6
150000001408 amides Chemical class 0.000 description 6
125000003710 aryl alkyl group Chemical group 0.000 description 6
125000001769 aryl amino group Chemical group 0.000 description 6
125000004391 aryl sulfonyl group Chemical group 0.000 description 6
125000005110 aryl thio group Chemical group 0.000 description 6
125000004104 aryloxy group Chemical group 0.000 description 6
125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
125000000753 cycloalkyl group Chemical group 0.000 description 6
125000004663 dialkyl amino group Chemical group 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
125000003106 haloaryl group Chemical group 0.000 description 6
125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 6
150000002576 ketones Chemical class 0.000 description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
125000002023 trifluoromethyl group Chemical class FC(F)(F)* 0.000 description 6
102100032938 Telomerase reverse transcriptase Human genes 0.000 description 4
238000000034 method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
150000001204 N-oxides Chemical class 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
125000005119 alkyl cycloalkyl group Chemical group 0.000 description 3
229910052785 arsenic Inorganic materials 0.000 description 3
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
229910052732 germanium Inorganic materials 0.000 description 3
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 3
210000002503 granulosa cell Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000004043 oxo group Chemical group O=* 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229940127557 pharmaceutical product Drugs 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
108091035539 telomere Proteins 0.000 description 3
210000003411 telomere Anatomy 0.000 description 3
102000055501 telomere Human genes 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000021595 spermatogenesis Effects 0.000 description 2
241000206602 Eukaryota Species 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
206010046764 Uterine atrophy Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
231100000502 fertility decrease Toxicity 0.000 description 1
230000008303 genetic mechanism Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000000203 mixture Chemical class 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
231100001042 uterine atrophy Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL257470A 2017-02-12 2018-02-11 תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך IL257470B2 (he)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
IL257470A IL257470B2 (he)	2018-02-11	2018-02-11	תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך
CA3053309A CA3053309C (en)	2017-02-12	2018-02-12	Telomerase activating compounds for use in fertility and related applications
AU2018218003A AU2018218003B2 (en)	2017-02-12	2018-02-12	Telomerase activating compounds for use in fertility and related applications
EP18709084.0A EP3579824A1 (en)	2017-02-12	2018-02-12	Telomerase activating compounds for use in fertility and related applications
CN201880024446.4A CN110505872A (zh)	2017-02-12	2018-02-12	用于生育力和相关应用的端粒酶活性化合物
PCT/IL2018/050161 WO2018146689A1 (en)	2017-02-12	2018-02-12	Telomerase activating compounds for use in fertility and related applications
US16/485,416 US11857516B2 (en)	2017-02-12	2018-02-12	Telomerase activating compounds for use in fertility and related applications
US18/456,178 US12576047B2 (en)	2017-02-12	2023-08-25	Telomerase activating compounds for use in fertility and related applications

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL257470A IL257470B2 (he)	2018-02-11	2018-02-11	תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך

Publications (3)

Publication Number	Publication Date
IL257470A IL257470A (he)	2018-03-29
IL257470B1 IL257470B1 (he)	2023-08-01
IL257470B2 true IL257470B2 (he)	2023-12-01

Family

ID=66624895

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL257470A IL257470B2 (he)	2017-02-12	2018-02-11	תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך

Country Status (1)

Country	Link
IL (1)	IL257470B2 (he)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008149345A2 (en) *	2007-06-04	2008-12-11	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
WO2015068156A1 (en) *	2013-11-05	2015-05-14	Ben-Gurion University Of The Negev Research And Development Authority	Compounds for the treatment of diabetes and disease complications arising from same

2018
- 2018-02-11 IL IL257470A patent/IL257470B2/he unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008149345A2 (en) *	2007-06-04	2008-12-11	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
WO2015068156A1 (en) *	2013-11-05	2015-05-14	Ben-Gurion University Of The Negev Research And Development Authority	Compounds for the treatment of diabetes and disease complications arising from same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOVEL TELOMERASE-INCREASING COMPOUND IN MOUSE BRAIN DELAYS THE ONSET OF AMYOTROPHIC LATERAL SCLEROSIS, ", 31 December 2012 (2012-12-31) *
OXIDATIVE STRESS PROTECTION BY NOVEL TELOMERASE ACTIVATORS IN MESENCHYMAL STEM CELLS DERIVED FROM HEALTHY AND DISEASED INDIVIDUALS, ", 31 December 2013 (2013-12-31) *

Also Published As

Publication number	Publication date
IL257470A (he)	2018-03-29
IL257470B1 (he)	2023-08-01

Publication	Publication Date	Title
JP5964898B2 (ja)	2016-08-03	テロメラーゼ活性化化合物及びその使用方法
CN110055243B (zh)	2024-03-26	反义核酸
WO2023225252A1 (en)	2023-11-23	Compositions and methods for inhibition of ras
CA3230542A1 (en)	2023-03-09	Novel ras inhibitors
DE69623655T2 (de)	2003-04-24	Chinolinderivate als gnrh antagonisten
CN101675054B (zh)	2014-05-14	环杷明内酰胺类似物及其使用方法
US20110293565A1 (en)	2011-12-01	Novel synthetic agonists of tlr9
KR20110092267A (ko)	2011-08-17	질환의 치료를 위한 히스타민 수용체의 아미노피리미딘 억제제
HK1243348A1 (zh)	2018-07-13	作为免疫调节剂的3-取代的-1，2，4-恶二唑和噻二唑化合物
KR102653599B1 (ko)	2024-04-01	질환 치료용 mct4 저해제
CN107427491A (zh)	2017-12-01	作为免疫调节剂的治疗性环状化合物
CN104606194A (zh)	2015-05-13	Pde4的双环杂芳基抑制剂
US20240180851A1 (en)	2024-06-06	Telomerase activating compounds for use in fertility and related applications
CA3107145A1 (en)	2020-02-27	Pyridinylmethylenepiperidine derivatives and uses thereof
CA3137901A1 (en)	2020-10-29	Heterocyclic inhibitors of tyrosine kinase
KR20200043434A (ko)	2020-04-27	아데노신 수용체 길항제로서의 퀴녹살린 유도체
HK1207570A1 (en)	2016-02-05	7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-4-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
KR20120051071A (ko)	2012-05-21	Ｐｄｅ４의 바이시클릭 헤테로아릴 억제제
EP3640245B1 (en)	2021-09-29	Poly(adp-ribose) polymerase inhibitor, preparation method and use
IL257470B1 (he)	2023-08-01	תרכובות מפעילי טלומרז לשימוש בפוריות ויישומים קשורים לכך
US7482352B2 (en)	2009-01-27	Chemical derivatives and their application as antitelomerase agents
US6174869B1 (en)	2001-01-16	Method for enhancing neurone survival and agents useful for same
CA3166298A1 (en)	2021-08-05	Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
CA3053309C (en)	2025-10-21	Telomerase activating compounds for use in fertility and related applications
JP2022510880A (ja)	2022-01-28	細胞内作用性毒素、細胞内のウイルス及び細菌に対する保護活性を示す新たなジヒドロキナゾリノン